Status of research and development of vaccines for chikungunya

Vaccine

Volumn 34, Issue 26, 2016, Pages 2976-2981

  Smalley, Claire ^a   Erasmus, Jesse H ^a   Chesson, Charles B ^a,b   Beasley, David W C ^a,b  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Alphavirus; Chikungunya; Emerging disease; Polyarthralgia; Vaccine

Indexed keywords

VIRUS VACCINE;

ARTICLE; CHIKUNGUNYA; CLINICAL FEATURE; DEVELOPING COUNTRY; DISEASE TRANSMISSION; DRUG APPROVAL; DRUG DESIGN; DRUG RESEARCH; HUMAN; HUMORAL IMMUNITY; MOSQUITO; PATHOPHYSIOLOGY; PRIORITY JOURNAL; VACCINATION; ANIMAL; CHIKUNGUNYA FEVER; CHIKUNGUNYA VIRUS; CLINICAL TRIAL (TOPIC); DISEASE MODEL; MEDICAL RESEARCH; TRENDS;

ANIMALS; BIOMEDICAL RESEARCH; CHIKUNGUNYA FEVER; CHIKUNGUNYA VIRUS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; VIRAL VACCINES;

EID: 84962439158     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.03.076     Document Type: Article

References (19)

1. Schwartz O., Albert M.L. Biology and pathogenesis of chikungunya virus. Nat Rev Microbiol 2010, 8(July (7)):491-500.
2. Weaver S.C., Osorio J.E., Livengood J.A., Chen R., Stinchcomb D.T. Chikungunya virus and prospects for a vaccine. Expert Rev Vaccines 2012, 11(September (9)):1087-1101.
3. Morrison T.E. Reemergence of chikungunya virus. J Virol 2014, 88(October (20)):11644-11647.
4. Weaver S.C., Lecuit M. Chikungunya virus infections. N Engl J Med 2015, 373(July (1)):94-95.
5. Pan American Health Organization program - Chikungunya 2015, PAHO, Available from: http://www.paho.org/hq/index.php?option=com_topics&view=article&id=343&Itemid=40931&lang=en [Website] [cited 05.08.15].
6. Soumahoro M.K., Boelle P.Y., Gauzere B.A., Atsou K., Pelat C., Lambert B., et al. The Chikungunya epidemic on La Reunion Island in 2005-2006: a cost-of-illness study. PLoS Negl Trop Dis 2011, 5(June (6)):e1197.
7. Yaseen H.M., Simon F., Deparis X., Marimoutou C. Estimation of lasting impact of a Chikungunya outbreak in Reunion Island. Epidemiology: Open Access 2012, 2:1-6.
8. Capeding M.R., Chua M.N., Hadinegoro S.R., Hussain I.I., Nallusamy R., Pitisuttithum P., et al. Dengue and other common causes of acute febrile illness in Asia: an active surveillance study in children. PLoS Negl Trop Dis 2013, 7(7):e2331.
9. Ray P., Ratagiri V.H., Kabra S.K., Lodha R., Sharma S., Sharma B.S., et al. Chikungunya infection in India: results of a prospective hospital based multi-centric study. PLoS ONE 2012, 7(2):e30025.
10. Yoon I.K., Alera M.T., Lago C.B., Tac-An I.A., Villa D., Fernandez S., et al. High rate of subclinical chikungunya virus infection and association of neutralizing antibody with protection in a prospective cohort in the Philippines. PLoS Negl Trop Dis 2015, 9(May (5)):e0003764.
11. Petitdemange C., Wauquier N., Vieillard V. Control of immunopathology during chikungunya virus infection. J Allergy Clin Immunol 2015, 135(April (4)):846-855.
12. Kam Y.W., Simarmata D., Chow A., Her Z., Teng T.S., Ong E.K., et al. Early appearance of neutralizing immunoglobulin G3 antibodies is associated with chikungunya virus clearance and long-term clinical protection. J Infect Dis 2012, 205(April (7)):1147-1154.
13. Chu H., Das S.C., Fuchs J.F., Suresh M., Weaver S.C., Stinchcomb D.T., et al. Deciphering the protective role of adaptive immunity to CHIKV/IRES a novel candidate vaccine against Chikungunya in the A129 mouse model. Vaccine 2013, 31(July (33)):3353-3360.
14. Hoen B. Prevention of mother-to-child transmission of Chikungunya infection: clinical evaluation of anti-CHIKV hyperimmune IVIg. Gaps and opportunities in Chikungunya research: expert consultation on Chikungunya disease in the Americas [presentation] 11/03/2015 2015, Available from: https://respond.niaid.nih.gov/conferences/chikungunya/documents/9 hoen bruno modified.pdf [cited 11.03.15].
15. Poo Y.S., Rudd P.A., Gardner J., Wilson J.A., Larcher T., Colle M.A., et al. Multiple immune factors are involved in controlling acute and chronic chikungunya virus infection. PLoS Negl Trop Dis 2014, 8(December (12)):e3354.
16. Rezza G. Do we need a vaccine against chikungunya?. Pathog Glob Health 2015, 109(June (4)):170-173.
17. Ahola T., Courderc T., Ng L.F., Hallengard D., Powers A., Lecuit M., et al. Therapeutics and vaccines against chikungunya virus. Vector Borne Zoonotic Dis 2015, 15(April (4)):250-257.
18. Chang L.J., Dowd K.A., Mendoza F.H., Saunders J.G., Sitar S., Plummer S.H., et al. Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial. Lancet 2014, 384(December (9959)):2046-2052.
19. Ramsauer K., Schwameis M., Firbas C., Mullner M., Putnak R.J., Thomas S.J., et al. Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial. Lancet Infect Dis 2015, 15(May (5)):519-527.